A multicenter cohort study, known as the PROFIT Study, has evaluated the predictive performance of various frailty assessment tools in forecasting one-year mortality among oncogeriatric patients aged 65 and older. This study involved 229 patients with a mean age of 75.1 years, predominantly male (68.6%), and a high incidence of advanced cancer (85.2% at stage IV). The frailty of these patients was assessed using the Geriatric 8 questionnaire (G8), Short Physical Performance Battery (SPPB), and the Frailty Index Indice Frágil—Valoración Integral Geriátrica (IF-VIG), with mortality tracked over one year.

The findings revealed that all assessment tools had predictive value for mortality, with IF-VIG exhibiting the highest sensitivity and SPPB showing the greatest specificity. Notably, optimized cut-offs for these tools enhanced their predictive performance compared to standard thresholds. The adjusted Cox regression models indicated significant associations between frailty and mortality, with hazard ratios of 1.97 for G8, 2.35 for SPPB, and 2.42 for IF-VIG, underscoring the clinical relevance of these assessments.

The study’s implications are significant for clinical practice and research in aging and oncology. The superior performance of SPPB and IF-VIG over G8 suggests a potential shift in frailty assessment protocols, advocating for the adoption of these tools to improve prognostic accuracy and inform treatment decisions for older cancer patients. This could ultimately enhance patient management strategies and outcomes in this vulnerable population, reinforcing the need for further exploration of frailty as a critical factor in oncogeriatric care.

Source: academic.oup.com